Dr. Neal I. Muni is an accomplished life sciences executive with over 20 years of industry experience as an operator, investor, and advisor to multiple biotechnology and pharmaceutical companies, leveraging unique insights gained through a career spanning industry, healthcare investment banking, the FDA, and clinical care.
Dr. Muni currently serves as the Managing Director of RTK Group, a family office backed biopharmaceutical advisory and investment fund focused on supporting clinical-stage companies from development to commercialization. As part of his operating and advisory roles through RTK Group, Dr. Muni serves as Advisor and Chief Medical Officer of Unravel Biosciences, Advisor and Partner at Romeg Therapeutics, Chief Operating Officer of Comera Life Sciences (NASDAQ:CMRA) and Independent Board Director of HDAX Therapeutics.
Prior to RTK Group, Dr. Muni served as the CEO of Azurity Pharmaceuticals, a commercial-stage pharmaceutical company focused on developing therapeutics for patients with high unmet need, including children and the elderly. During his tenure as CEO, Dr. Muni achieved a successful investor exit and company sale to private equity upon receiving FDA approval of the company’s lead program.
Prior to Azurity, Dr. Muni served as the Head of New Product Planning and Corporate Strategy at Sunovion Pharmaceuticals. Prior to that, Dr. Muni was an engagement manager at the healthcare investment bank Leerink Swann. Prior to Leerink, he was a Medical Officer in the Division of Cardiovascular Devices at the FDA.
Over the past 20 years, Dr. Muni has maintained staff appointments at Harvard Medical School and its leading teaching hospitals, including Brigham and Women’s Hospital, Dana Farber Cancer Institute, and Faulkner Hospital. Dr. Muni is also appointed as a Visiting Scholar at Harvard University’s Wyss Institute for Biologically Inspired Engineering, mentoring project teams on technology development, entrepreneurship and company formation. Dr. Muni completed his residency in Internal Medicine at the Brigham and is appointed as Associate Physician on the hospitalist service. Dr. Muni received his MD as well as Master of Science in Public Health (biostatistics) from the Tulane University School of Medicine, and a BA in Business Economics and B.Sc. in Biochemistry from Brown University.
At the Wyss Institute, Neal is a member of the Wyss Mentor Hive who specializes in therapeutics, FDA regulation, clinical development, Investigational New Drug-enabling studies, and commercialization. As a mentor, Neal works closely with Wyss project teams and collaborates on technology development, partnering, and company formation.
The Wyss Mentor Hive is a mentoring program that invites investors and business professionals with significant early stage translational experience, clinical and regulatory experts in driving therapeutic and device development, and serial entrepreneurs with a track record of success to work closely with Wyss entrepreneur teams on startup formation and technology commercialization. Mentors provide feedback to founders and entrepreneurs, while also demonstrating commitment and leadership in the Wyss innovation community.